Halozyme Therapeutics

Halozyme to expand in San Francisco

Thursday, November 19, 2015

Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, will be expanding its facilities by opening a satellite office on Gateway Boulevard in South San Francisco. Halozyme is based in San Diego and currently has about 200 employees.

[Read More]

Halozyme taps Labarre as chief scientific officer

Monday, August 31, 2015

Halozyme Therapeutics, a San Diego-based biotechnology company developing novel oncology and drug-delivery therapies, has named Michael J. LaBarre, Ph.D., as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. The move broadens LaBarre’s responsibilities to include R&D of early pipeline assets, in addition to his role managing product development and ENHANZE platform partnerships.

[Read More]

Halozyme names Laurie Stelzer CFO

Monday, June 8, 2015

Halozyme Therapeutics, an oncology biotech company headquartered in San Diego, has announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume chief financial officer  duties on June 15 and will work with Ramsay through a transition period.

[Read More]

Roche’s Herceptin phase III trial shows positive results

Tuesday, October 18, 2011

Halozyme Therapeutics has reported that the phase III HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

[Read More]

Halozyme launches phase II pancreatic cancer trial

Thursday, October 6, 2011

Halozyme Therapeutics has reported the commencement of patient dosing in a phase II clinical trial with pegylated rHuPH20 (PEGPH20) in patients with stage IV previously untreated pancreatic cancer. This multi-center, international, randomized, placebo-controlled trial will study the safety, tolerability and efficacy of gemcitabine plus PEGPH20 compared to gemcitabine plus placebo.

[Read More]

Halozyme’s ultrafast insulin demonstrates reduced variability of insulin absorption

Sunday, June 26, 2011

Halozyme Therapeutics has announced final results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme’s rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog, reduces the variability of insulin absorption and reduces post-meal glycemic excursions compared to NovoLog alone.

[Read More]

Halozyme’s ultrafast insulin study shows positive results

Friday, April 15, 2011

Halozyme Therapeutics reports results from a study in type I diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme’s rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLogR, accelerates insulin absorption and shortened its duration of action. These preliminary results represent the first reported experience in a clinical trial where patients received rHuPH20 enzyme combined with an insulin analog as a continuous subcutaneous insulin infusion (CSII) over 72 hours administered with an insulin pump.

[Read More]